Trial Profile
First line treatment with rituximab plus fludarabine, cyclophosphamide, mitoxantrone (R-FCM) and maintenance therapy with rituximab in patients diagnosed with chronic lymphocytic leukemia.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Aug 2015
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Fludarabine; Mitoxantrone
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 18 Aug 2015 New trial record